the evaluation of effectiveness of oral silymarin on memory status of patients with dementia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201505091856N5

Enrollment

100

Registered

2015-05-22

Start date

2015-05-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Dementia in Alzheimer disease. Condition 2: Vascular dementia. Condition 3: Dementia in other diseases classified elsewhere. Alzheimer disease is a primary degenerative cerebral disease of unknown etiology with characteristic neuropathological and neurochemical features. The disorder is usually insidious in onset and develops slowly but steadily over a period of several years. Vascular dementia is the result of infarction of the brain due to vascular disease, including hypertensiv

Interventions

Intervention 1: Silymarin, 140 mg tablets, 3 times a day (trade name, Livergol, goldaru company), for 12 weeks. Intervention 2: Placebo tablets identical to silymarin tablets in shape and color, 3 tim

Treatment - Drugs

Placebo

Silymarin, 140 mg tablets, 3 times a day (trade name, Livergol, goldaru company), for 12 weeks

Placebo tablets identical to silymarin tablets in shape and color, 3 times a day, for 12 weeks. Placebo tablets are made in pharmacology faculty of kermanshah university of medical sciences.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion criteria: 1. definite diagnosis of dementia by an experienced neurologist 2. at least one year has past form the time of the diagnosis exclusion criteria: 1. illiterate persons 2. having epilepsy, cardiovascular diseases, metabolic diseases, respiratory diseases, orthopedic problems and renal failure with serum cratinin level more than 2 3. history of previous stroke 4. acute and severe state of any disease including stroke, pulmonary infection, renal disease, metabolic disturbance or trauma leading to hospitalization during the study 5. using other self care programs that are effective on memory state of patents at the same time of study intervention

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Memory status of patients. Timepoint: before and 12 weeks after intervention. Method of measurement: mini mental state examination scale.	—

Secondary

Measure	Time frame
Drug side effects. Timepoint: 12 weeks after intervention. Method of measurement: history and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Daryoush Afshari

Kermanshah University of Medical Sciences

dafshari@kums.ac.irafshari_d@yahoo.com+98 83 3427 6326

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026